Adaptive Biotechnologies Corporation (ADPT)

Adaptive Biotechnologies Corporation is trading at $25.63, up 4.36% on the session. The 50 day average sits at $21.20 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 59.9, which reads as strong, and MACD is bearish crossover. Volume is below average.

The nearest support is around $21.74 with resistance near $26.16, so that band frames the current range. Average daily movement is roughly $1.26, or about 4.9% of the share price, which is what any stop placement has to allow for. The overall health score of 61 out of 100 combines a trend score of 75, momentum of 62 and a risk score of 36.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.